Aadi Bioscience (AADI) has provided an update.
Loretta Itri, M.D., is stepping down as Chief Medical Officer but will receive a generous severance package and maintain a consulting role with her former company. Neil Desai, Ph.D., also plans to leave his role as Executive Chairman, with a severance in line with his agreement. Both will continue their involvement with the company, Itri through consulting and Desai as a board member, allowing them to retain their equity awards. This move could signal strategic shifts or a refresh in leadership, offering potential impacts on the company’s direction and stock performance.
For a thorough assessment of AADI stock, go to TipRanks’ Stock Analysis page.
